Nasla Loya
Family · Tacoma, WANPI 1467875013
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,511 of the $9,561 with a category attached, or 78.6%. 26 manufacturers reported payments, led by AbbVie at 40.1% of the total. 2025 is the largest year on record at $4,312, more than ten times the $14 reported in 2021. Among family clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 224 payments — averaging $42.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Johnson & Johnson$1K
- Pfizer$953
- Takeda Pharmaceuticals U.S.A., Inc.$717
- Phathom Pharmaceuticals, Inc.$510
- Lilly USA, LLC$312
- plus $2K from 20 others
What the payments were for
- Speaking & faculty fees$1,93920%
- Travel & lodging$20%
- Food & beverage$7,51179%
- Education$1091%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 73 | $3,830 |
| Johnson & Johnson | 37 | $1,205 |
| Pfizer | 12 | $953 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $717 |
| Phathom Pharmaceuticals, Inc. | 13 | $510 |
| Lilly USA, LLC | 9 | $312 |
| Janssen Scientific Affairs, LLC | 8 | $292 |
| E.r. Squibb & Sons, L.L.C. | 3 | $278 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $233 |
| Regeneron Healthcare Solutions, Inc. | 3 | $171 |
| Aimmune Therapeutics, Inc. | 4 | $140 |
| QOL Medical, LLC | 4 | $125 |
| Ardelyx, Inc. | 5 | $111 |
| Conmed Corporation | 1 | $108 |
| Gilead | 1 | $107 |
| Organon | 5 | $97 |
| Celltrion USA Inc. | 4 | $86 |
| Sanofi | 2 | $66 |
| Bristol Myers Squibb | 3 | $48 |
| Novo Nordisk | 2 | $42 |
| Braintree Laboratories, Inc. | 1 | $28 |
| Merck | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Intercept Pharmaceuticals, Inc. | 1 | $17 |
| Exact Sciences | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,561 in reported general payments places this provider in the 95th percentile of 1,706 family providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 11 | $329,018 |
| CreonLipase/Protease/Amylase | 31 | $80,207 |
| LinzessLinaclotide | 78 | $63,858 |
| Mesalamine | 18 | $9,328 |
| Pantoprazole Sodium | 161 | $2,419 |
| Omeprazole | 104 | $2,221 |
| CholestyramineCholestyramine (With Sugar) | 13 | $1,678 |
| Lubiprostone | 26 | $1,623 |
| Famotidine | 81 | $1,467 |
| Dicyclomine Hcl | 35 | $811 |
| Azathioprine | 15 | $737 |
| Lactulose | 18 | $666 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 31 | $652 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 31 | $544 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 25 | $472 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $1,205 | $329,01811 claims |
| AbbVieCreon, Linzess | $3,830 | $144,064109 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,706 family providers in Washington.
Other family in Tacoma
- Tammi HudspethTacoma$8K
- Michelle HendrickxTacoma$7K
- Simon KatumuTacoma$6K
- Sharla PetersonKenmore$192K
- Zelda SwainSpokane$83K
- Savannah MorganRenton$76K
- Kevan PettersonSeattle$56K
- Kelly McFeeSunnyside$42K
- Cheryl SomersSpokane$31K
- Hye-Jin GehringBellevue$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.